• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23537 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     National Institute for Health and Care Excellence (NICE) Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 891
2023     National Institute for Health and Care Excellence (NICE) Difelikefalin for treating pruritus in people having haemodialysis. NICE technology appraisal guidance 890
2023     National Institute for Health and Care Excellence (NICE) Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 889
2023     National Institute for Health and Care Excellence (NICE) Risankizumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 888
2023     National Institute for Health and Care Excellence (NICE) Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 887
2023     National Institute for Health and Care Excellence (NICE) Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy. NICE technology appraisal guidance 886
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 885
2023     National Institute for Health and Care Excellence (NICE) Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal). NICE technology appraisal guidance 884
2023     National Institute for Health and Care Excellence (NICE) Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 883
2023     National Institute for Health and Care Excellence (NICE) Voclosporin with mycophenolate mofetil for treating lupus nephritis. NICE technology appraisal guidance 882
2023     National Institute for Health and Care Excellence (NICE) Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments. NICE technology appraisal guidance 881
2023     National Institute for Health and Care Excellence (NICE) Tezepelumab for treating severe asthma. NICE technology appraisal guidance 880
2023     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal). NICE technology appraisal guidance 879
2023     National Institute for Health and Care Excellence (NICE) Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. NICE technology appraisal guidance 878
2023     National Institute for Health and Care Excellence (NICE) Finerenone for treating chronic kidney disease in type 2 diabetes. NICE technology appraisal guidance 877
2023     National Institute for Health and Care Excellence (NICE) Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer. NICE technology appraisal guidance 876
2023     National Institute for Health and Care Excellence (NICE) Semaglutide for managing overweight and obesity. NICE technology appraisal guidance 875
2023     National Institute for Health and Care Excellence (NICE) Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. NICE technology appraisal guidance 874
2023     National Institute for Health and Care Excellence (NICE) Cannabidiol for treating seizures caused by tuberous sclerosis complex. NICE technology appraisal guidance 873
2023     National Institute for Health and Care Excellence (NICE) Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 872
2023     National Institute for Health and Care Excellence (NICE) Eptinezumab for preventing migraine. NICE technology appraisal guidance 871
2023     National Institute for Health and Care Excellence (NICE) Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. NICE technology appraisal guidance 870
2023     National Institute for Health and Care Excellence (NICE) Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal). NICE technology appraisal guidance 869
2023     National Institute for Health and Care Excellence (NICE) Vutrisiran for treating hereditary transthyretin-related amyloidosis. NICE technology appraisal guidance 868
2023     National Institute for Health and Care Excellence (NICE) Mitapivat for treating pyruvate kinase deficiency (terminated appraisal). NICE technology appraisal guidance 867
2023     National Institute for Health and Care Excellence (NICE) Regorafenib for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 866
2023     National Institute for Health and Care Excellence (NICE) Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. NICE technology appraisal guidance 865
2023     National Institute for Health and Care Excellence (NICE) Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted. NICE technology appraisal guidance 864
2023     National Institute for Health and Care Excellence (NICE) Somatrogon for treating growth disturbance in children and young people aged 3 years and over. NICE technology appraisal guidance 863
2023     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments. NICE technology appraisal guidance 862
2023     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating active non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 861
2023     National Institute for Health and Care Excellence (NICE) Maribavir for treating refractory cytomegalovirus infection after transplant. NICE technology appraisal guidance 860
2023     National Institute for Health and Care Excellence (NICE) Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal). NICE technology appraisal guidance 859
2023     National Institute for Health and Care Excellence (NICE) Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 858
2023     National Institute for Health and Care Excellence (NICE) Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma. NICE technology appraisal guidance 857
2023     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 856
2023     National Institute for Health and Care Excellence (NICE) Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. NICE technology appraisal guidance 855
2023     The Danish Health Technology Council (DHTC) [High-tech hospital beds for use in intensive and neurological wards]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after the deadline (diffuse large B-cell lymphoma, (DLBCL))]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after the deadline: B-cell acute lymphoblastic leukaemia (ALL), relapsed/ refractory, 0 ≤ 25 years)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Talquetamab (multiple myeloma, at least 3 prior therapies)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Setmelanotide (new therapeutic indication: obesity and control of hunger, Bardet-Biedl syndrome, ≥ 6 years)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ivosidenib (cholangiocarcinoma with IDH1 R132 mutation, after at least 1 prior therapy)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Lonapegsomatropin (growth failure due to growth hormone deficiency, ≥ 3 to < 18 years)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Fenfluramine (new therapeutic indication: Lennox-Gastaut syndrome, add-on therapy, ≥ 2 years)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Etranacogene dezaparvovec (haemophilia B)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Belantamab mafodotin (reassessment after the deadline: multiple myeloma, at least 4 prior therapies, monotherapy)]
2023     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ciltacabtagene autoleucel (relapsing/ refractory multiple myeloma, after at least 3 prior therapies)]
2023     Center for Drug Evaluation (CDE) [Latest trend in consumption and utilization of schedule I and II controlled drugs - a nationwide population-based data in Taiwan
2023     Ontario Health Carrier screening programs for cystic fibrosis, fragile X syndrome, hemoglobinopathies and thalassemia, and spinal muscular atrophy
2023     Ontario Health Robotic-assisted hysterectomy for endometrial cancer in people with obesity
2023     Ontario Health Robotic-assisted partial nephrectomy for kidney cancer
2023     National Authority for Assessment and Accreditation in Healthcare (INEAS) [Autologous adipose-derived stem cells for chronic wounds treatment : Full HTA report]
2023     National Authority for Assessment and Accreditation in Healthcare (INEAS) [Kadcyla® (trastuzumab emtansine) in the treatment of HER2-positive breast cancer : A rapid review]
2023     The Regional Health Technology Assessment Centre (HTA-centrum) [Remote patient monitoring– an overview of systematic reviews for selected diagnosis groups]
2023     The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy and safety of advanced hybrid closed loop systems compared with multiple daily injections or open loop systems, in adults with type 1 diabetes
2023     The Regional Health Technology Assessment Centre (HTA-centrum) General psychiatric management for patients with personality disorder and/or self-harm behaviour
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of andexanet alfa (Ondexxya)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odronextamab (diffuse large B-cell lymphoma in adults); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Odronextamab (follicular lymphoma in adults); assessment according to §35a Social Code Book V; search for disease registries]
2023     Center for Drug Evaluation (CDE) [Assessment of the optimal implementation strategy for pneumococcal vaccination policies in groups at high risk of invasive pneumococcal disease]
2023     Center for Drug Evaluation (CDE) [Evaluation of the optimal fixed subsidies strategy for pneumococcal vaccination in the elderly]
2023     Center for Drug Evaluation (CDE) [Review of domestic and international drug addiction replacement treatment policies and cost-effectiveness analysis of methadone treatment in Taiwan]
2023     Center for Drug Evaluation (CDE) [Analysis of the effectiveness of various hemophilia treatments in Taiwan]
2023     Center for Drug Evaluation (CDE) [Evaluation of the effectiveness of long-acting antipsychotic injections and future recommendations for mental health care in Taiwan's National Health Insurance System]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: innovations in home support, at the crossroads of humanity and technology]
2023     Basque Office for Health Technology Assessment (OSTEBA) [Massive parallel sequencing for the diagnosis of acute leukaemia]
2023     Health Sciences Institute in Aragon (IACS) [Molecular study of common apoE gene polymorphisms associated with familial dysbetalipoproteinaemia and late-onset Alzheimer’s disease]
2023     Agency for Care Effectiveness (ACE) KardiaMobile for the detection of atrial fibrillation
2023     Agency for Care Effectiveness (ACE) AcQMap for patients with cardiac arrhythmia
2023     Agency for Care Effectiveness (ACE) Rapid to aid the diagnosis of patients suspected of stroke
2023     Agency for Care Effectiveness (ACE) HeartFlow FFRCT for the diagnosis of coronary artery disease
2023     Agency for Care Effectiveness (ACE) Paige Prostate Detect to assist the diagnosis of prostate cancer
2023     Agency for Care Effectiveness (ACE) The CADScor System as a rule-out test for symptomatic patients suspected to have coronary artery disease
2023     Agency for Care Effectiveness (ACE) Optune for the treatment of newly diagnosed and recurrent glioblastoma
2023     Agency for Care Effectiveness (ACE) MagTrace and SentiMag for locating sentinel lymph node in patients with breast cancer
2023     Agency for Care Effectiveness (ACE) Zio XT for ambulatory ECG monitoring for patients suspected to have cardiac arrhythmia
2023     Agency for Care Effectiveness (ACE) Cytosponge for the detection of patients with Barrett oesophagus
2023     Agency for Care Effectiveness (ACE) Sirolimus-coated percutaneous transluminal coronary angioplasty balloon catheters (SCBs) for patients with coronary artery disease (CAD)
2023     Agency for Care Effectiveness (ACE) Thoracic and abdominal endovascular repair (T/EVAR) for the structural support of aortic aneurysm
2023     Agency for Care Effectiveness (ACE) Aortic hybrid stent graft for treating complex aortic disease
2023     Agency for Care Effectiveness (ACE) SpaceOAR systems for rectum protection during prostate cancer treatment
2023     Agency for Care Effectiveness (ACE) Minimally invasive glaucoma surgery (MIGS) implants for treating patients with mild to moderate primary open-angle glaucoma (POAG)
2023     Agency for Care Effectiveness (ACE) Presbyopia-correcting intraocular lenses for treating patients with cataract
2023     Agency for Care Effectiveness (ACE) Dexamethasone intravitreal implant for treating diabetic macular oedema, retinal vein occlusion and non-infectious uveitis
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies
2023     Agency for Care Effectiveness (ACE) Botulinum toxin A for the management of focal spasticity of the lower limbs associated with stroke in adults
2023     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis
2023     Agency for Care Effectiveness (ACE) Romosozumab and teriparatide for treating osteoporosis
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sirolimus (Facial angiofibroma in tuberous sclerosis) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Talquetamab (multiple myeloma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lonapegsomatropin (growth hormone deficiency) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pitolisant (narcolepsy, with or without cataplexy, children and adolescents, 6-17 years) – Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (psoriatic arthritis) – Addendum to Commission A23-60]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for etranacogene dezaparvovec (haemophilia B) acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version 1.0) – Second addend]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pegunigalsidase alfa (Fabry disease) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Benefit assessment according to §35a Social Code Book V]